Sareum Holdings (SAR) RNS Announcements

Add to Alert list
Date Time Source Announcement
26 Oct 2020 11:05 AM
RNS
Second Price Monitoring Extn
26 Oct 2020 11:00 AM
RNS
Price Monitoring Extension
20 Oct 2020 01:00 PM
RNS
Exercise of Share Options and Director Dealings
13 Oct 2020 07:01 AM
RNS
Full Year Results Investor Presentation
13 Oct 2020 07:00 AM
RNS
Final Results
12 Oct 2020 04:41 PM
RNS
Second Price Monitoring Extn
12 Oct 2020 04:36 PM
RNS
Price Monitoring Extension
08 Oct 2020 07:00 AM
RNS
US Patent Allowance: SDC-1802 TYK2/JAK1 Inhibitor
12 Aug 2020 07:00 AM
RNS
Details of Investor Presentation
11 Aug 2020 07:00 AM
RNS
Trading Statement
29 Jul 2020 02:05 PM
RNS
Second Price Monitoring Extn
29 Jul 2020 02:00 PM
RNS
Price Monitoring Extension
24 Jul 2020 07:00 AM
RNS
Research Update
01 Jul 2020 07:00 AM
RNS
Update on Deferred Salaries and Issue of Equity
03 Jun 2020 11:06 AM
RNS
Second Price Monitoring Extn
03 Jun 2020 11:00 AM
RNS
Price Monitoring Extension
03 Jun 2020 07:00 AM
RNS
Successful Fundraising
02 Jun 2020 04:31 PM
RNS
PrimaryBid.com Offer
02 Jun 2020 04:30 PM
RNS
Placing to raise £718,500
27 May 2020 07:00 AM
RNS
Sareum to Present at BIO Digital 2020
01 May 2020 07:00 AM
RNS
BioTrinity Presentation Available Online
28 Apr 2020 07:00 AM
RNS
Company Presentation at BioTrinity
20 Apr 2020 11:00 AM
RNS
Price Monitoring Extension
17 Apr 2020 11:05 AM
RNS
Second Price Monitoring Extn
17 Apr 2020 11:00 AM
RNS
Price Monitoring Extension
14 Apr 2020 11:06 AM
RNS
Second Price Monitoring Extn
14 Apr 2020 11:01 AM
RNS
Price Monitoring Extension
26 Mar 2020 07:00 AM
RNS
Half-year Report
26 Mar 2020 07:00 AM
RNS
Global Licensing of FL3+Aurora Programme
12 Mar 2020 07:00 AM
RNS
Publication: new SRA737 combinations in cancer
17 Dec 2019 01:36 PM
RNS
Result of AGM
17 Dec 2019 07:00 AM
RNS
AGM Statement
20 Nov 2019 07:00 AM
RNS
Notice of AGM
05 Nov 2019 10:56 AM
RNS
Sareum notes Sierra Oncology Q3 2019 results
30 Oct 2019 07:00 AM
RNS
Research Update - SDC-1802 anti-cancer poster
17 Oct 2019 07:00 AM
RNS
Research Update - AACR-NCI-EORTC abstract
15 Oct 2019 07:00 AM
RNS
Final Results
07 Oct 2019 07:00 AM
RNS
Notice of Full Year Results
27 Sep 2019 07:00 AM
RNS
Research Update - TYK2/JAK1 cancer programme
27 Aug 2019 07:00 AM
RNS
Trading Statement
16 Aug 2019 07:00 AM
RNS
Change of Adviser
08 Aug 2019 02:17 PM
RNS
Sareum notes Sierra Q2 results
29 Jul 2019 04:29 PM
RNS
Additional disclosure concerning Michael Owen
28 Jun 2019 07:00 AM
RNS
Additional Funds Raised
27 Jun 2019 01:50 PM
RNS
Sierra seeks strategic options for SRA737
26 Jun 2019 07:00 AM
RNS
Successful Fundraising
25 Jun 2019 04:31 PM
RNS
PrimaryBid.com Offer
25 Jun 2019 04:30 PM
RNS
Placing to progress TYK2/JAK1 programmes
13 Jun 2019 07:00 AM
RNS
Portfolio Update
03 Jun 2019 04:00 PM
RNS
Key takeaways from SRA737 webcast at ASCO

Sareum Holdings Plc (Sareum) is a clinical-stage drug discovery and development company that produces targeted small-molecule therapeutics for treating cancer and autoimmune diseases.

The drug research programs of the company are based on its proprietary drug discovery technology, Sareum Kinase Inhibitor Library (SKIL). The company delivers drug candidates for licensing to biotechnology and pharmaceutical companies at the pre-clinical or early clinical trials stage. Its research programs include Chk1 (checkpoint kinase 1), Aurora+FLT3 kinase, Autoimmune-TYK2/JAK1 kinases, and Cancer-TYK2/JAK1 kinases. Sareum's Chk1 kinase cancer research program is being conducted through joint research collaboration with Cancer Research Technology Limited and the Institute of Cancer Research. Sareum is headquartered in Cambridge, the UK.

It listed on AIM in 2004 under the ticker SAR.

UK 100

Latest directors dealings